link Issuer Direct STANS, Switzerland, Feb. 25, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the following upcoming investor conferences: Livingston Securities Healthcare and Emerging Growth CEO Series on Thursday, February 25, 2021 at 11:30am Eastern Time (5:30pm CET). Maxim 2021 Emerging Growth Virtual Conference hosted by M-Vest on March 17, 2021. The Company's presentation for this conference will be available on M-Vest following the conference. A bout NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary controlled release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Corporate contact Alex Zwyer, CEO: +41 41 618 80 00 Investor Relations contact David Moskowitz: +1 202-280-0888 www.nlspharma.com SOURCE NLS Pharmaceutics Ltd. This website uses cookies for analysis. You can find exact details in our privacy policy. No thank youOk Partnerships Contact NLS Pharmaceutics AG Alter Postplatz 2 CH-6370 Stans NW Switzerland P: +41 41 618 80 00 F: +41 41 618 80 09 contact@nls-pharma.com About NLS Science News Investors About Contact Legal Privacy Policy Terms and Conditions Cookie Policy Follow us ©2021 NLS Pharmaceutics. All rights reserved.

Leadership Team Led by our Co-Founder and CEO, Alexander Zwyer, the senior leadership team at NLS is made up of experienced professionals skilled in many disciplines with a successful track record for developing innovative products in the pharmaceutical industry Alex Zwyer Silvia Panigone Eric Konofal Subhasis Roy Executive Board Roland Hafner add Alex Zwyer add Myoung-Ok Kwon add Stig Loekke Pedersen add Gian-Marco Rinaldi add This website uses cookies for analysis. You can find exact details in our privacy policy. No thank youOk Partnerships Contact NLS Pharmaceutics AG Alter Postplatz 2 CH-6370 Stans NW Switzerland P: +41 41 618 80 00 F: +41 41 618 80 09 contact@nls-pharma.com About NLS Science News Investors About Contact Legal Privacy Policy Terms and Conditions Cookie Policy Follow us ©2021 NLS Pharmaceutics. All rights reserved.